United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Martingale Asset Management L P

Martingale Asset Management L P decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 13.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,102 shares of the biotechnology company's stock after selling 5,664 shares during the period. Martingale Asset Management L P owned about 0.08% of United Therapeutics worth $13,296,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. LSV Asset Management raised its holdings in shares of United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company's stock valued at $307,837,000 after purchasing an additional 436,851 shares in the last quarter. FMR LLC raised its stake in United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock valued at $386,168,000 after buying an additional 314,004 shares in the last quarter. Assetmark Inc. lifted its holdings in United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company's stock worth $150,492,000 after buying an additional 152,249 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company's stock worth $178,972,000 after acquiring an additional 92,240 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of United Therapeutics by 49.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company's stock valued at $88,089,000 after acquiring an additional 91,597 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on UTHR. Jefferies Financial Group upped their price target on United Therapeutics from $315.00 to $432.00 and gave the company a "buy" rating in a report on Monday, September 23rd. Argus increased their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. HC Wainwright boosted their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Finally, Wells Fargo & Company upped their target price on United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a research report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $370.86.

United Therapeutics Stock Down 2.0 %

NASDAQ:UTHR traded down $7.64 during midday trading on Friday, reaching $370.49. The stock had a trading volume of 211,330 shares, compared to its average volume of 456,724. The stock has a market cap of $16.54 billion, a P/E ratio of 16.27, a P/E/G ratio of 1.10 and a beta of 0.56. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The firm has a fifty day simple moving average of $367.77 and a two-hundred day simple moving average of $335.19.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business's quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.38 earnings per share. On average, sell-side analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 7,785 shares of the business's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the sale, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. The trade was a 74.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Judy D. Olian sold 1,750 shares of the business's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $412.48, for a total transaction of $721,840.00. Following the completion of the sale, the director now owns 5,655 shares in the company, valued at $2,332,574.40. This represents a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 127,227 shares of company stock worth $47,398,820. Company insiders own 11.90% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.